Methods for preventing and treating type ii diabetes
AssigneeThe Jackson Laboratory
InventorMichael Stitzel
Life of this patent
Estimating the term…
Abstract
Provided herein, in some aspects, are methods for preventing or treating diabetes in a subject, the method comprising assaying a genomic sample obtained from the subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A gene (C2CD4A) and a C2 calcium-dependent domain containing 4B gene (C2CD4B), and when the intergenic variant is present in the genomic sample, administering to the subject a therapy for diabetes. Also provided herein are rodent cells homozygous for a C2cd4a mutation and/or homozygous for a C2cd4h mutation, and methods for producing the rodent cells.
Claims42
A cell in a transgenic animal, the cell comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.
A cell comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.
A method for producing a C2cd4a−/− rodent cell, the method comprising:
- introducing into the rodent cell a gRNA or a nucleic acid encoding a gRNA that targets a C2cd4a gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
- optionally culturing the cell;
- and
- producing the C2cd4a−/− rodent cell.
A method for producing a C2cd4b−/− rodent cell, the method comprising:
- introducing into the rodent cell a gRNA or a nucleic acid encoding a gRNA. that targets a C2cd4b gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or nucleic acid encoding a Cas nuclease;
- optionally culturing the cell;
- and
- producing the C2c4b−/− rodent cell.
A method for producing a C2cd4a−/−/C2cd4b−/− rodent cell, the method comprising:
- introducing into the rodent cell a nucleic acid encoding a gRNA that targets a C2cd4a gene and a nucleic acid encoding a gRNA that targets a C2cd4b gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
- optionally culturing the cell;
- and
- producing the C2cd4a−/−/C2cd4b−/− rodent cell.
A mouse cell homozygous for a C2cd4a mutation and homozygous for a C2cd4b mutation, optionally wherein the mouse cell is from a NZO/HILtJ mouse.
A method for preventing or treating diabetes in a subject, the method comprising:
- assaying a genomic sample obtained from a subject for a single nucleotide polymorphism (SNP) selected from rs4502156 allele (T), rs1881415 allele (T), rs67818839 allele (A), rs7162757 rs8037894 allele (G), rs8038040 allele (G), rs6494307 allele (C), rs7161785 allele (G), rs7167878 allele (C), rs7167932 allele (C), rs7172432 allele (A), rs7173964 allele (G), rs4775466 allele (C), rs4775467 allele (G), rs10083587 allele (C), and rs11856307 allele (A);
- and
- when the SNP is present in the genomic sample, administering to the subject a therapy to prevent or treat diabetes in the subject.
A method for preventing or treating diabetes in a subject, the method comprising:
- assaying a genomic sample obtained from a subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A (C2CD4A) gene and a C2 calcium-dependent domain containing 4B (C2CD4B) gene;
- measuring a level of proinsulin in a biological sample obtained from the subject;
- and
- when the intergenic variant is present in the genomic sample and the level of proinsulin in the biological sample is greater than 20 pmol/L, administering to the subject a therapy to prevent or treat diabetes in the subject.
A transgenic mouse comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.
Dependencies are inferred from the claim text.